AbbVie Inc. 8-K

What Happened

• AbbVie filed a Form 8‑K on January 7, 2026 (Item 2.02) saying its preliminary results for the quarter ended December 31, 2025 include $1.3 billion of acquired IPR&D and milestone expenses (pre-tax). AbbVie said this charge produces an unfavorable impact of $0.71 to both GAAP diluted EPS and adjusted (non‑GAAP) diluted EPS for Q4 2025.
• The company noted quarter-end results have not been finalized and remain subject to its financial closing procedures, so final reported figures could differ.

Key Details

• $1.3 billion pre-tax acquired IPR&D and milestones expense recorded in Q4 2025.
• Estimated EPS impact: negative $0.71 to GAAP diluted EPS and adjusted diluted EPS for Q4 2025.
• AbbVie updated 2025 full‑year adjusted diluted EPS guidance to $9.90 – $9.94 (this range includes the Q4 acquired IPR&D impact).
• AbbVie’s Q4 2025 adjusted diluted EPS guidance range (including the charge): $2.61 – $2.65.

Why It Matters

• The $1.3B charge is a large, one‑time expense that reduces both reported (GAAP) and adjusted (non‑GAAP) EPS for Q4 and affects the company’s full‑year adjusted EPS guidance. That can materially change short‑term earnings metrics investors use to evaluate performance.
• AbbVie cautions these are preliminary estimates and historically does not forecast acquired IPR&D/milestone charges because their timing and occurrence are uncertain. Investors should watch for the finalized quarterly results and the company’s regular filings for confirmation.